You are here

P&T October 2014

Features

Time, Expense, and Quality of Results Are at Issue, As Is the Relationship to Drug Pricing

Costly medications have raised questions about the role that long, complex clinical trials play in drug pricing. Approval of a drug takes, on average, 14 years, costs more than $2 billion, and has a high risk of failure. Participants are seeking alternatives.

Pharmacovigilance Forum

Elevated uric acid levels can cause crystal deposition and may lead to gout, urolithiasis, and urate nephropathy. The authors report on the case of a 34-year-old male whose hyperuricemia was associated with the antituberculous drug pyrazinamide.

Knowledge of Tumors’ Molecular Diversity Is Opening New Pathways to Treatment

Lung cancer treatment has undergone significant change in the past decade, leading to remarkable growth in the number and variety of therapeutic options. This shift reflects, in part, a significant refinement in the molecular categorization of lung cancer.

3D printing is expected to revolutionize health care through uses in tissue and organ fabrication; creation of customized prosthetics, implants, and anatomical models; and pharmaceutical research regarding drug dosage forms, delivery, and discovery.

Pipeline Plus

Treatment of Parkinson’s disease is expected to lead to $3.56 billion in global sales in 2022. Manufacturers are reformulating medications in addition to creating new ones.

Departments

Medication Errors
Telling true stories can help improve medication safety.
Prescription: Washington

The FDA has accepted its first biosimilar application.

FDA approvals, drug indications, and updates

Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia

Drug Forecast

Edoxaban: an investigational factor Xa inhibitor